Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) just unveiled an announcement.
AstraZeneca has admitted 45,750 additional ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market, bringing the total number of shares in issue to 1,550,980,332. The new shares, which are fully fungible with existing ordinary shares, were issued between 20 January and 19 March 2026 under the company’s pre-existing block admission.
These shares were created to satisfy awards under AstraZeneca’s employee share schemes and did not require a new prospectus, reflecting routine equity issuance rather than a capital-raising transaction. The move modestly increases the company’s share count but primarily underscores AstraZeneca’s ongoing use of equity-based compensation to align employees with long-term shareholder interests.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £240.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, U.K., focused on the discovery, development and commercialisation of prescription medicines. Its core therapeutic areas include oncology, rare diseases, and a broad BioPharmaceuticals portfolio spanning cardiovascular, renal and metabolism, as well as respiratory and immunology, with products sold in over 125 countries.
Average Trading Volume: 2,622,931
Technical Sentiment Signal: Buy
Current Market Cap: £218.9B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.